Circulating miRNA-21 as early potential diagnostic biomarker for acute myocardial infarction: a meta-analysis.

IF 2.8 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Frontiers in Cardiovascular Medicine Pub Date : 2024-08-22 eCollection Date: 2024-01-01 DOI:10.3389/fcvm.2024.1330884

Ke Wang, Kai Li, Zhuoyuan Li, Xizhang Yan

{"title":"Circulating miRNA-21 as early potential diagnostic biomarker for acute myocardial infarction: a meta-analysis.","authors":"Ke Wang, Kai Li, Zhuoyuan Li, Xizhang Yan","doi":"10.3389/fcvm.2024.1330884","DOIUrl":null,"url":null,"abstract":"Introduction: There exists a knowledge gap concerning the clinical significance of miRNA-21; therefore, in the present study, we aimed to estimate the diagnostic and prognostic accuracy and sensitivity of miRNA-21 in acute myocardial infarction (AMI) by performing an evidence-based meta-analysis of previous AMI-related clinical studies.Methods: Chinese and English literature published before April 2024 were searched, and data were reviewed and extracted. After quality appraisal, the STATA 16.0 software was used for the effect size analysis of the various treatments described in the literature.Results: A total of 14 valid documents were retrieved from 562 studies. The results of the systematic review revealed that for the patients with AMI vs. those without non-AMI, the aggregated odds ratio reached 5.37 (95% confidence interval 3.70-7.04). The general sensitivity and specificity for the circulating miRNA-21 levels in diagnosing AMI were 0.83 and 0.81, respectively.Discussion: Thus, the meta-analysis of 14 AMI-related clinical trials highlighted that miRNA-21 may serve as a promising biomarker for diagnosing AMI.","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11374624/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Cardiovascular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fcvm.2024.1330884","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: There exists a knowledge gap concerning the clinical significance of miRNA-21; therefore, in the present study, we aimed to estimate the diagnostic and prognostic accuracy and sensitivity of miRNA-21 in acute myocardial infarction (AMI) by performing an evidence-based meta-analysis of previous AMI-related clinical studies.

Methods: Chinese and English literature published before April 2024 were searched, and data were reviewed and extracted. After quality appraisal, the STATA 16.0 software was used for the effect size analysis of the various treatments described in the literature.

Results: A total of 14 valid documents were retrieved from 562 studies. The results of the systematic review revealed that for the patients with AMI vs. those without non-AMI, the aggregated odds ratio reached 5.37 (95% confidence interval 3.70-7.04). The general sensitivity and specificity for the circulating miRNA-21 levels in diagnosing AMI were 0.83 and 0.81, respectively.

Discussion: Thus, the meta-analysis of 14 AMI-related clinical trials highlighted that miRNA-21 may serve as a promising biomarker for diagnosing AMI.

查看原文本刊更多论文

循环 miRNA-21 作为急性心肌梗死的早期潜在诊断生物标志物：一项荟萃分析。

引言关于miRNA-21的临床意义存在知识空白，因此，在本研究中，我们旨在通过对既往AMI相关临床研究进行循证荟萃分析，估计miRNA-21在急性心肌梗死（AMI）中的诊断和预后准确性及敏感性：方法：检索2024年4月之前发表的中英文文献，并对数据进行回顾性分析和提取。方法：检索 2024 年 4 月前发表的中英文文献，并提取数据，经过质量评估后，使用 STATA 16.0 软件对文献中描述的各种治疗方法进行效应大小分析：结果：共从 562 项研究中检索到 14 篇有效文献。系统综述结果显示，急性心肌梗死患者与非急性心肌梗死患者的总几率比为 5.37（95% 置信区间为 3.70-7.04）。循环 miRNA-21 水平诊断 AMI 的一般敏感性和特异性分别为 0.83 和 0.81：因此，对14项AMI相关临床试验的荟萃分析强调，miRNA-21可作为诊断AMI的一种有前途的生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Cardiovascular Medicine Medicine-Cardiology and Cardiovascular Medicine

CiteScore

3.80

自引率

11.10%

发文量

3529

审稿时长

14 weeks

期刊介绍： Frontiers? Which frontiers? Where exactly are the frontiers of cardiovascular medicine? And who should be defining these frontiers? At Frontiers in Cardiovascular Medicine we believe it is worth being curious to foresee and explore beyond the current frontiers. In other words, we would like, through the articles published by our community journal Frontiers in Cardiovascular Medicine, to anticipate the future of cardiovascular medicine, and thus better prevent cardiovascular disorders and improve therapeutic options and outcomes of our patients.

文献相关原料

公司名称	产品信息	采购帮参考价格